147 related articles for article (PubMed ID: 3259469)
1. Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice.
Roth JA; Ames RS; Fry K; Lee HM; Scannon PJ
Cancer Res; 1988 Jun; 48(12):3496-501. PubMed ID: 3259469
[TBL] [Abstract][Full Text] [Related]
2. Analysis of gp74 expression by transformed rat fibroblasts from experimental pulmonary metastases following specific ricin A-chain immunotoxin therapy.
Roth JA; Thomsen S; Fry KD; Scannon P; Chang C
Cancer Res; 1989 Oct; 49(20):5708-12. PubMed ID: 2676148
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody 45-2D9 conjugated to the A chain of ricin is specifically toxic to c-Ha-ras-transfected NIH 3T3 cells expressing gp74.
Roth JA; Ames RS; Byers V; Lee HM; Scannon PJ
J Immunol; 1986 Mar; 136(6):2305-10. PubMed ID: 3950414
[TBL] [Abstract][Full Text] [Related]
4. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
7. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
[TBL] [Abstract][Full Text] [Related]
10. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
Leonard JE; Johnson DE; Shawler DL; Dillman RO
Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
[TBL] [Abstract][Full Text] [Related]
12. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
13. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
Colombatti M; Dell'Arciprete L; Chignola R; Tridente G
Cancer Res; 1990 Mar; 50(5):1385-91. PubMed ID: 2302703
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.
Byers VS; Pimm MV; Pawluczyk IZ; Lee HM; Scannon PJ; Baldwin RW
Cancer Res; 1987 Oct; 47(20):5277-83. PubMed ID: 3498532
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
16. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Calvete JA; Newell DR; Wright AF; Rose MS
Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
[TBL] [Abstract][Full Text] [Related]
20. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
